Earnings News - Candlesense

Eagle Point Income Company Inc. Announces Second Quarter 2025 Financial Results and Declares Fourth Quarter 2025 Common and Preferred Distributions

GREENWICH, Conn.--(BUSINESS WIRE)---- $EIC--Eagle Point Income Company Inc. (the “Company”) (NYSE: EIC, EICA, EICB, EICC) today announced financial results for the quarter ended June 30, 2025 and c...

Are there any tax or regulatory considerations related to the preferred stock distributions that could affect investor returns? Will the Q2 results trigger any changes in analyst sentiment or target price adjustments for the stock? What macro‑economic or market conditions could influence the company's cash flow and distribution sustainability moving forward?

Symbol: EIC

27 days ago

Read more businesswire

BioXcel Therapeutics Reports Second Quarter 2025 Financial Results and Recent Business Updates

Topline data from SERENITY At-Home Phase 3 trial for acute treatment of agitation associated with bipolar disorders or schizophrenia expected in August

How does the expected data release align with broader market sentiment toward biotech earnings and macro‑economic conditions? What are the potential regulatory implications if the trial meets its endpoints, and how could that affect the timeline to market and revenue forecasts? How might the trial outcomes influence analyst coverage, earnings estimates, and forward‑looking guidance for BioXcel?

Symbol: BXY

27 days ago

Read more globenewswire

Sypris Reports Second Quarter Results

LOUISVILLE, Ky.--(BUSINESS WIRE)---- $SYPR--Sypris Solutions, Inc. (Nasdaq/GM: SYPR) today reported financial results for its second quarter ended June 29, 2025. HIGHLIGHTS ────────────────────────...

Are there any upcoming strategic initiatives or cost‑saving measures that could offset the negative effects of the tariffs? What is the cash flow and liquidity position after the Q2 results, and are there any concerns about working capital needs? Does management provide any guidance for future quarters regarding tariff impacts and demand recovery?

Symbol: SYPR

27 days ago

Read more businesswire

Mereo BioPharma Reports Second Quarter 2025 Financial Results and Provides Corporate Highlights

Data from Phase 3 Orbit and Cosmic studies of setrusumab in osteogenesis imperfecta expected around year-end 2025

What macro or sector factors could amplify or dampen the stock's reaction to the Phase 3 results? How does the current earnings performance compare to prior quarters and what does that imply for cash runway ahead of the data readout? Are there any contingent financing or partnership arrangements tied to the Phase 3 outcomes that could influence the stock?

Symbol: MERE

27 days ago

Read more globenewswire

ZenaTech Reports Over 500% Increase in Year-Over-Year Revenue for Second Quarter of 2025 and Over 250% Increase in Revenue for the First Six Months of Year

VANCOUVER, British Columbia, Aug. 12, 2025 (GLOBE NEWSWIRE) -- ZenaTech, Inc. (Nasdaq: ZENA) (FSE: 49Q) (BMV: ZENA) ("ZenaTech"), a technology business solution provider specializing in AI (Artif...

Will the company consider issuing additional shares or other financing to support its growth initiatives? How is the defense industry business progressing, and what impact could it have on future revenue? Is there any planned capital allocation (e.g., R&D, capex, M&A) that could affect future earnings?

Symbol: ZENA

27 days ago

Read more globenewswire

Madison Square Garden Sports Corp. Reports Fiscal 2025 Fourth Quarter and Full-Year Results

NEW YORK--(BUSINESS WIRE)--Madison Square Garden Sports Corp. (NYSE: MSGS) today reported financial results for the fiscal fourth quarter and full-year ended June 30, 2025. The fiscal 2025 fourth q...

How did the company’s guidance and results affect the stock’s intraday price movement and trading volume after the release? Are there any risks highlighted in the filing (e.g., player injuries, labor negotiations, or regulatory changes) that could affect future earnings? What impact might the Knicks’ performance in the Eastern Conference Finals have on future ticket pricing and fan engagement metrics?

Symbol: MSGS

27 days ago

Read more businesswire

Anavex Life Sciences Reports Fiscal 2025 Third Quarter Financial Results and Provides Business Update

Company to host a webcast today at 8:30 a.m. Eastern Time

What is the expected impact of any changes in the capital structure, such as stock issuances or debt financing, on dilution and shareholder value? Did the company announce any strategic partnerships, collaborations, or licensing deals that could materially affect its competitive position? What potential regulatory or reimbursement risks were highlighted that could affect future earnings?

Symbol: AVXL

27 days ago

Read more globenewswire

Kopin Corporation Reports Financial Results for the Second Quarter 2025

WESTBOROUGH, Mass.--(BUSINESS WIRE)--Kopin Corporation (“Kopin” or “the Company”) (Nasdaq: KOPN), a leading developer and provider of high-performance application-specific optical solutions consist...

How did the stock react immediately after the release, and what is the current trading volume relative to average daily volume? What risks were highlighted in the risk factors section of the filing (e.g., supply chain, regulatory, geopolitical) that could affect the stock? What are the analyst consensus and target price changes following this earnings release?

Symbol: KOPN

27 days ago

Read more businesswire

Mobilicom Reports Financial and Operational Results for the Six Months Ended June 30, 2025

Momentum accelerates with $1.5 million in revenue for H1 2025 and an order backlog of $1.6 million as of June 30, bringing the combined total to $3.1 million — already approaching full-year 2024 re...

How might the earnings results influence short‑term technical indicators and trading volume for MOBI? Is there any indication that the company will raise its full‑year revenue guidance or issue a share buy‑back? What potential risks could derail the continued ramp‑up of sales in H2 2025 (e.g., supply chain, regulatory, customer concentration)?

Symbol: MOBI

27 days ago

Read more globenewswire

Milestone Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Regulatory and Corporate Update

FDA Accepted the Company’s Response to the CRL for CARDAMYST™ (etripamil) Nasal Spray; New PDUFA Target Date of December 13, 2025

What are the broader implications for MLND's pipeline and future cash flow projections given the revised regulatory timeline? How might this news affect the trading volume and liquidity of MLND shares in the short term? Will the updated timeline impact analyst coverage or consensus estimates for MLND's 2025 financial performance?

Symbol: MLND

27 days ago

Read more globenewswire